The AhR pathway is often dysregulated in AD, with increased AhR expression and reduced activation of its downstream targets, such as CYP1A1, suggests a dysfunctional pathway that fails to exert its full anti-inflammatory effects. This evidence concerns the gene AHR and Alzheimer disease.